Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The importance of indirect screening and objective gold standards: a response to Terplan (2012).

Ondersma SJ, Svikis DS, Lebreton JM, Streiner DL, Grekin ER, Lam PK, Connors-Burge V.

Addiction. 2013 May;108(5):1002. doi: 10.1111/add.12131. No abstract available.

PMID:
23587087
2.

Commentary on Ondersma et‚ÄČal. (2012): beyond the quest for the perfect test-drug use screening in pregnancy.

Terplan M.

Addiction. 2012 Dec;107(12):2107-8. doi: 10.1111/j.1360-0443.2012.04094.x. No abstract available.

PMID:
23167646
3.

Development and preliminary validation of an indirect screener for drug use in the perinatal period.

Ondersma SJ, Svikis DS, LeBreton JM, Streiner DL, Grekin ER, Lam PK, Connors-Burge V.

Addiction. 2012 Dec;107(12):2099-106. doi: 10.1111/j.1360-0443.2012.03982.x. Epub 2012 Aug 10.

4.
5.

Detection of prenatal drug exposure in the pregnant women and her newborn infant.

Ostrea EM Jr, Welch RA.

Clin Perinatol. 1991 Sep;18(3):629-45. Review.

PMID:
1934859
6.

Assessment of perinatal substance abusers: experiences of one Perinatal-20 project.

Haller DL, Ingersoll KS.

NIDA Res Monogr. 1996;166:143-62. No abstract available.

PMID:
8818170
7.

Detection of prenatal drug exposure in the pregnant woman and her newborn infant.

Ostrea EM Jr.

NIDA Res Monogr. 1992;117:61-79. Review. No abstract available.

PMID:
1620211
8.

Substance abuse in pregnant women: making improved detection a good clinical outcome.

Araojo R, McCune S, Feibus K.

Clin Pharmacol Ther. 2008 Apr;83(4):520-2. doi: 10.1038/clpt.2008.13.

PMID:
18349872
9.

Drug use and pregnancy - challenges for public health.

Gyarmathy VA, Giraudon I, Hedrich D, Montanari L, Guarita B, Wiessing L.

Euro Surveill. 2009 Mar 5;14(9):33-6.

10.

Novel methods for the detection of drug and alcohol exposure during pregnancy: implications for maternal and child health.

Koren G, Hutson J, Gareri J.

Clin Pharmacol Ther. 2008 Apr;83(4):631-4. doi: 10.1038/sj.clpt.6100506. Epub 2008 Feb 20. Review.

PMID:
18288086
11.

Gastric fluid analysis for determining gestational cocaine exposure.

Garcia DC, Romero A, Garcia GC, Ostrea EM Jr.

Pediatrics. 1996 Aug;98(2 Pt 1):291-3. No abstract available.

PMID:
8692634
12.

Detection of drug use during pregnancy.

Kwong TC, Shearer D.

Obstet Gynecol Clin North Am. 1998 Mar;25(1):43-64. Review.

PMID:
9547759
13.

Routine urine drug screening at the first prenatal visit.

Colmorgen GH, Johnson C, Zazzarino MA, Durinzi K.

Am J Obstet Gynecol. 1992 Feb;166(2):588-90.

PMID:
1536237
14.

Identification of polysubstance abuse in the parturient.

Birnbach DJ, Browne IM, Kim A, Stein DJ, Thys DM.

Br J Anaesth. 2001 Sep;87(3):488-90.

PMID:
11517135
15.

Emerging biomarkers of intrauterine neonatal and pediatric exposures to xenobiotics.

Delano K, Koren G.

Pediatr Clin North Am. 2012 Oct;59(5):1059-70. doi: 10.1016/j.pcl.2012.07.005. Epub 2012 Aug 22. Review.

PMID:
23036244
16.

Perinatal substance abuse and neonatal abstinence.

Christophersen R, D'Apolito K, Bakewell-Sachs S.

J Perinat Neonatal Nurs. 2014 Jul-Sep;28(3):157-8. doi: 10.1097/JPN.0000000000000047. No abstract available.

PMID:
25062513
17.

Anonymous testing for drug abuse in an antenatal population.

Farkas AG, Colbert DL, Erskine KJ.

Br J Obstet Gynaecol. 1995 Jul;102(7):563-5. No abstract available.

PMID:
7647061
18.

Screening for illicit drug use.

Lin KW, Finnell VW.

Am Fam Physician. 2009 Sep 15;80(6):629. No abstract available.

19.

Meconium drug screening to detect prenatal substance abuse.

Wildman KM, Mohl V, Houston R, Allerheiligen D.

J Fam Pract. 1996 Nov;43(5):501-2. No abstract available.

PMID:
8917151
20.

Measuring prenatal drug exposure.

Bergin C, Cameron CE, Fleitz RS, Patel AV.

J Pediatr Nurs. 2001 Aug;16(4):245-55.

PMID:
11498817

Supplemental Content

Support Center